Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer
Despite clinical benefits, pembrolizumab combined with chemotherapy for advanced biliary tract cancer is not cost-effective at current prices and willingness-to-pay thresholds. Adjusting drug pricing and healthcare policies is crucial for enhancing the global economic viability of this treatment strategy.
Authors
- Quanyi Liu (ORCID: https://orcid.org/0000-0002-6333-699X)
- Shu‐Yuan Xiao (ORCID: https://orcid.org/0009-0002-2678-3798)
- Xia Li (ORCID: https://orcid.org/0000-0002-2213-6166)
- Yun Gu
- Lin Qiu (ORCID: https://orcid.org/0000-0003-0802-7155)
- Yinghong Xie
Institutions
- Dalian Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
- Dali University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-08-11
- DOI
- https://doi.org/10.3389/fpubh.2025.1597550
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01